Pfizer - McKnight's Long Term Care News


Also in the News for Wednesday, Jan. 10

Pfizer ends its quest to develop Alzheimer’s and Parkinson’s drugs … Nearly 70 Wisconsin seniors fear eviction amid Medicaid dispute … Hawaiian program gives family caregivers who work a daily stipend

Also in the news for August 15, 2014 . . .

High-dose flu vaccine about 25% more effective for seniors … Regular internet use reduces dementia risk in seniors, scientists say … Expert panel recommends seniors receive Pfizer pneumonia vaccine … TX lawmakers propose ‘3 strikes’ rule to close nursing homes


Pfizer must pay $142 million for the marketing and prescribing of epilepsy drug Neurontin for unapproved uses, a federal appeals court has ruled. The justices refused to overturn a jury’s previous verdict. The jury determined Pfizer marketed Neurontin for bipolar disorder, migraines and neuropathic pain. The Food and Drug Administration had not approved the medicine for any of those uses.

Experimental drug prevents blood clots from forming in legs and lungs

The experimental drug Eliquis prevented blood clots in the legs and lungs and kept them from recurring, according to a new study. Patients who took the medicine were 81% less likely to have symptoms of a clot or die than those who received a placebo, according to findings published in the New England Journal of Medicine.

FDA approves Pfizer's rheumatoid arthritis treatment

FDA approves Pfizer’s rheumatoid arthritis treatment

Federal regulators recently approved Pfizer’s new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate.

Following Hurricane Sandy, drug makers get back to business

The typical long-term care resident requires eight or more medications daily. So with Hurricane Sandy ripping through the pharmaceutical corridor last week, many operators were rightfully concerned about possible medication shortages. The good news is that most drug firms appear to be getting back on their feet quickly

Next post in Products